| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alectinib induced vitiligo with rapid re-pigmentation
|
Wang, Meng
|
|
|
200 |
C |
p.
|
artikel
|
| 2 |
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
|
Chorti, Eleftheria
|
|
|
200 |
C |
p.
|
artikel
|
| 3 |
Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study
|
Ebstein, E.
|
|
|
200 |
C |
p.
|
artikel
|
| 4 |
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies
|
Zaun, Gregor
|
|
|
200 |
C |
p.
|
artikel
|
| 5 |
Corrigendum to “Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer” [Eur J Cancer 180 (2023) 184–185]
|
Yang, Fan
|
|
|
200 |
C |
p.
|
artikel
|
| 6 |
Editorial Board
|
|
|
|
200 |
C |
p.
|
artikel
|
| 7 |
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
|
Mark, Michael
|
|
|
200 |
C |
p.
|
artikel
|
| 8 |
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
|
Lindemann, Kristina
|
|
|
200 |
C |
p.
|
artikel
|
| 9 |
Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial
|
Topkan, Erkan
|
|
|
200 |
C |
p.
|
artikel
|
| 10 |
Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy
|
Matsuo, Koji
|
|
|
200 |
C |
p.
|
artikel
|
| 11 |
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
|
Rusakiewicz, S.
|
|
|
200 |
C |
p.
|
artikel
|
| 12 |
Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival
|
Pire, Aurore
|
|
|
200 |
C |
p.
|
artikel
|
| 13 |
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
|
Parisi, Alessandro
|
|
|
200 |
C |
p.
|
artikel
|
| 14 |
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
|
Noronha, Vanita
|
|
|
200 |
C |
p.
|
artikel
|
| 15 |
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
|
Egeler, Mees
|
|
|
200 |
C |
p.
|
artikel
|
| 16 |
Recent advances and future strategies in first-line treatment of ES-SCLC
|
Gomez-Randulfe, Igor
|
|
|
200 |
C |
p.
|
artikel
|
| 17 |
Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy
|
Fournier, Marie
|
|
|
200 |
C |
p.
|
artikel
|
| 18 |
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial
|
Diéras, Véronique
|
|
|
200 |
C |
p.
|
artikel
|
Tijdschrift beschrijving